Business Context and Reporting Period
Company: AnaptysBio, Inc. (ANAB)
Filing Type: Form 8-K (Current Report)
Date: February 12, 2025
Event: Announcement of top-line data from the Phase 2b RENOIR clinical trial for rosnilimab in moderate-to-severe rheumatoid arthritis (RA).
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details the results of the global 424-patient Phase 2b RENOIR trial evaluating rosnilimab (a PD-1+ T cell depleter and agonist) in RA patients on background cDMARDs.
- Primary Endpoint: Achieved statistical significance for mean change from baseline in DAS-28 CRP at Week 12 across all three doses versus placebo.
- Secondary Endpoints: Demonstrated statistical significance in at least one dose and numerical superiority at all doses for ACR20, ACR50, and CDAI Low Disease Activity (LDA) at Week 12.
- Week 14 Data: 69% of rosnilimab-treated patients achieved CDAI LDA. This includes 71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced patients.
- Week 28 Outlook: Patients achieving CDAI LDA at Week 14 continued treatment. Data as of December 10, 2024, suggests sustained responses and potentially deepening ACR70 responses. Complete Week 28 data is anticipated in Q2 2025.
- Biomarkers: Observed ~90% reduction in PD-1high T cells, ~50% reduction in PD-1+ T cells, and increased total Tregs, indicating robust on-target activity.
Guidance, Outlook, and Risks
Safety Profile: The trial demonstrated a favorable safety and tolerability profile through Week 12 and for patients continuing to Week 28. Key observations include:
- No malignancies or Major Adverse Cardiac Events (MACE).
- No elevation of serious infections compared to placebo.
- No anaphylaxis or systemic hypersensitivity.
- Low incidence of injection site reactions, similar to placebo.
Forward-Looking Statements: The company anticipates complete Week 28 data in Q2 2025. The filing includes standard disclaimers regarding risks related to clinical trial timing, regulatory approval, commercialization, funding, and intellectual property.
Investor Verification Checklist
- Verify the timing and content of the anticipated complete Week 28 data release in Q2 2025.
- Review the full safety data for the subset of patients continuing to Week 28 once the blinded period concludes.
- Assess the company's cash runway and funding requirements given the ongoing clinical development phase.
- Monitor regulatory discussions regarding the path to Phase 3 trials based on these Phase 2b results.